Glenmark Pharmaceuticals Europe Limited is recalling one batch after stability testing showed out-of-specification results. The batch is being recalled as a precautionary measure following test results that showed a delay in capsule dissolution.
Similar Posts
Field Safety Notices: 10 to 14 November 2025
List of Field Safety Notices from 10 to 14 November 2025.
Guidance: Medical devices: examples of reportable incidents
Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.
Guidance: Herbal medicines granted a traditional herbal registration (THR)
A list of herbal medicines currently holding a traditional herbal registration (THR) granted by the Medicines and Healthcare products Regulatory Agency (MHRA).
MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours.
MHRA welcomes Professor Jonathan Benger CBE as new CEO of NICE
Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration
MHRA approves zuranolone to treat postnatal depression in adults following childbirth
As with any medicine, the MHRA will keep the safety of zuranolone under close review.